Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 543Neoplasms 449Carcinoma, Non-Small-Cell Lung 410Prostatic Neoplasms 334Colorectal Neoplasms 315Lung Neoplasms 261Multiple Myeloma 229Neoplasm Metastasis 190Pancreatic Neoplasms 186Leukemia, Myeloid, Acute 183Ovarian Neoplasms 178Melanoma 147Squamous Cell Carcinoma of Head and Neck 140Carcinoma, Hepatocellular 116Recurrence 115Head and Neck Neoplasms 114Carcinoma, Renal Cell 112Lymphoma 111Stomach Neoplasms 110Endometrial Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Glioblastoma 108Brain Neoplasms 106Lymphoma, Non-Hodgkin 105Uterine Cervical Neoplasms 100Triple Negative Breast Neoplasms 97Urinary Bladder Neoplasms 95Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84

Interventions

Miransertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Proteus Syndrome × 30 days × Clear all
NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
38 enrolled

Proteus Syndrome

NCT00001403 2026-05-22

Study of Proteus Syndrome and Related Congenital Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
1,500 enrolled

Abnormalities, Multiple, Growth Disorders, Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡